Tara A. Byrne

Tara A. Byrne


Partner, New York

Tara Byrne has experience in all aspects of complex patent litigation in technologies within the pharmaceutical, chemical and biological arts. She has represented leaders in these technological fields, including Bristol-Myers Squibb, AstraZeneca, Novartis, Sanofi, LEO Pharma, Adams Respiratory Therapeutics and Reckitt Benckiser in litigation involving pharmaceutical compounds and compositions. Ms. Byrne has extensive experience in litigating ANDA cases brought under the Hatch-Waxman Act. Tara also has experience representing clients in litigation brought by non-practicing entities (NPEs) and litigating breach of contract and misappropriation of trade secret matters. She also has experience in counseling clients on licensing and other agreements.

Tara is also a licensed Professional Engineer in the State of New York and the State of Vermont. 

Tara is Chair of the firm’s Diversity Committee and Chair of the Women’s Initiative Program.

Case Highlight
Adams Respiratory Therapeutics, Inc et al. v. Perrigo Company et al. 
Fed. Cir. (2010) 

Obtained a favorable ruling from the U.S. Court of Appeals for the Federal Circuit in litigation involving a patent covering Reckitt Benckiser’s very successful and popular over-the-counter drug product Mucinex®.
Representative Matters
  • Bristol-Myers Squibb against BenVenue on patents relating to the cancer drug Taxol®.
  • AstraZeneca against several generic challengers including Andrx, Genpharm, Dr. Reddy’s and Kremers Urban Development Co. relating to AstraZeneca’s blockbuster proton-pump inhibitor drug Prilosec®.
  • AstraZeneca against Ivax on a patent relating to AstraZeneca’s calcium channel-blocker drug Plendil®.
  • AstraZeneca against Andrx, Eon and KV Pharmaceuticals on patents relating to AstraZeneca’s beta-blocker drug Toprol-XL®.
  • Novartis against Breckenridge, Roxane, Taro and Teva on a patent relating to Novartis’s anti-epileptic drug Trileptal®.
  • Novartis against Barr, Abrika and KV on patents relating to Novartis’s Ritalin LA® Product.
  • Novartis against Teva on patents relating to Novartis’s Focalin IR® product.
  • Novartis against Teva, IPC, Par, Actavis, Barr, KV, and Mylan on patents relating to Novartis’s Focalin XR® product.
  • Sanofi-Aventis against several generic challengers in an ANDA litigation relating to Sanofi's Eloxatin® product.
  • Adams Respiratory Therapeutics and Reckitt Benckiser against Perrigo and Watson in ANDA litigations relating to the drug Mucinex®.
  • Sanofi-Aventis against Genentech and Biodec on a patent relating to Sanofi’s Avastin® and Rituxan® products.
  • Novartis against Mylan on patents relating to Novartis’s Myfortic® product.
  • LEO Pharma against Tolmar on patents relating to LEO Pharma’s Dovonex® and Taclonex® products.
  • EdisonLearning against Alternatives Unlimited in a breach of contract/misappropriation of trade secrets claim.
  • American Express as indemnitor to Delta Airlines in litigation brought by Walker Digital, on patents relating to a system for assembly of retail packages.
  • American Express in a litigation brought by LBS Innovations on a patent relating to a wireless system for providing information about places and events.